# A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

> **NCT02287233** · PHASE1,PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 94 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- AML

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02287233
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-31
- **Primary completion:** 2021-08-10
- **Final completion:** 2021-08-10
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2022-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287233, "A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02287233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*